.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
McKinsey
Johnson and Johnson
Dow
Medtronic
Julphar
Teva
Argus Health
AstraZeneca

Generated: July 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208294

« Back to Dashboard
NDA 208294 describes BEVESPI AEROSPHERE, which is a drug marketed by Astrazeneca Pharms and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the BEVESPI AEROSPHERE profile page.

The generic ingredient in BEVESPI AEROSPHERE is formoterol fumarate; glycopyrrolate. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the formoterol fumarate; glycopyrrolate profile page.

Summary for NDA: 208294

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 208294

Suppliers and Packaging for NDA: 208294

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION 208294 NDA AstraZeneca Pharmaceuticals LP 0310-4600 0310-4600-12 120 AEROSOL, METERED in 1 INHALER (0310-4600-12)
BEVESPI AEROSPHERE
formoterol fumarate; glycopyrrolate
AEROSOL, METERED;INHALATION 208294 NDA AstraZeneca Pharmaceuticals LP 0310-4600 0310-4600-28 28 AEROSOL, METERED in 1 INHALER (0310-4600-28)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.0048MG/INH;0.0090MG/INH
Approval Date:Apr 25, 2016TE:RLD:Yes
Regulatory Exclusivity Expiration:Apr 25, 2019
Regulatory Exclusivity Use:NEW PRODUCT
Patent:► SubscribePatent Expiration:May 28, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Patent:► SubscribePatent Expiration:May 28, 2030Product Flag?Substance Flag?Delist Request?
Patented Use:USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Teva
Cerilliant
Julphar
Mallinckrodt
Express Scripts
Deloitte
Citi
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot